Perflubutane
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Perflubutane
- DrugBank Accession Number
- DB12821
- Background
Perflubutane has been used in trials studying the diagnostic of Liver Mass, Liver Diseases, Liver Metastasis, Portal Hypertension, and Peripheral Artery Disease. It is a cardiovascular drug designed to enable ultrasound to compete more effectively with nuclear stress testing; currently the leading procedure for detecting coronary heart disease.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 238.028
Monoisotopic: 237.98403163 - Chemical Formula
- C4F10
- Synonyms
- Decafluorobutane
- Perflubutane
- perflubutano
- Sonazoid
- External IDs
- AI-700
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Perflubutane perfusion echocardiography has the potential to be a cost-effective and convenient alternative to nuclear perfusion imaging. Perflubutane is easy to use and echocardiographers in the clinical trials can be trained to use it after imaging only a few patients. Based on data from previous clinical trials, ultrasound enhanced with Perflubutane was able to image myocardial perfusion and obtain information that appears comparable to nuclear imaging. Acusphere's Phase 3 program is designed with the appropriate comparative standards to determine the value of Perflubutane perfusion echocardiography relative to nuclear perfusion imaging. These standards are coronary angiography, nuclear perfusion imaging, and patient outcome.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Perflubutane can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Almasilate Almasilate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminium phosphate Aluminium phosphate can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. Aluminum hydroxide Aluminum hydroxide can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Perflubutane resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as organofluorides. These are compounds containing a chemical bond between a carbon atom and a fluorine atom.
- Kingdom
- Organic compounds
- Super Class
- Organohalogen compounds
- Class
- Organofluorides
- Sub Class
- Not Available
- Direct Parent
- Organofluorides
- Alternative Parents
- Hydrocarbon derivatives / Alkyl fluorides
- Substituents
- Aliphatic acyclic compound / Alkyl fluoride / Alkyl halide / Hydrocarbon derivative / Organofluoride
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- SE4TWR0K2C
- CAS number
- 355-25-9
- InChI Key
- KAVGMUDTWQVPDF-UHFFFAOYSA-N
- InChI
- InChI=1S/C4F10/c5-1(6,3(9,10)11)2(7,8)4(12,13)14
- IUPAC Name
- decafluorobutane
- SMILES
- FC(F)(F)C(F)(F)C(F)(F)C(F)(F)F
References
- General References
- Hamilos MI, Patrianakos AP: AI-700 (Acusphere). Curr Opin Investig Drugs. 2005 Sep;6(9):956-61. [Article]
- External Links
- PubChem Compound
- 9638
- PubChem Substance
- 347828991
- ChemSpider
- 13862701
- ChEBI
- 134964
- ChEMBL
- CHEMBL2104979
- ZINC
- ZINC000056897668
- Wikipedia
- Perfluorobutane
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Diagnostic Focal Nodular Hyperplasia 1 somestatus stop reason just information to hide Not Available Completed Diagnostic Hepatocellular Carcinoma / Microwave Ablation 1 somestatus stop reason just information to hide Not Available Unknown Status Not Available Stage I Endometrial Carcinoma 1 somestatus stop reason just information to hide 4 Completed Diagnostic Liver Disease / Portal Hypertension 1 somestatus stop reason just information to hide 3 Completed Diagnostic Coronary Artery Disease (CAD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0485 mg/mL ALOGPS logP 3.63 ALOGPS logP 3.48 Chemaxon logS -3.7 ALOGPS Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 0 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 3 Chemaxon Refractivity 22.21 m3·mol-1 Chemaxon Polarizability 9.22 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 141.41086 predictedDeepCCS 1.0 (2019) [M+H]+ 143.80641 predictedDeepCCS 1.0 (2019) [M+Na]+ 149.80234 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 00:30 / Updated at February 21, 2021 18:54